Home
About
Cancer
- Current Treatments
- Market
Therapies
Investors
Contact
Glossary of Terms
Search
Menu Menu

cancure cancer treatments

INVESTORS

Investors Snapshot
News
Public Documents

NEWS

NousCom receives $49M to trial off-the-shelf cancer vaccine
AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans
Incyte pays MacroGenics $150M for PD-1 inhibitor
Gilead buys CAR-T developer Kite Pharma for $12B

Contact

Mr Craig Miles
craig@cancure.com
+61 (0) 408 778 797
PO Box 1177, Broadbeach,
Queensland, Australia 4218

Copyright © 2021 All rights reserved.

Twitter
Dribbble